

Supplementary Table 1 Demographics of the osteoporosis patients involved in this study


	Control	OP
Patient number	6	6
Gender	Female	Female
Age	63.75 ± 2.99	66.25 ± 1.89
Bone density (T-score ± SD)	-0.18 ± 0.55	-2.93 ± 0.10

Supplementary Table 2 Primers used in this study


Gene symbol	Accession number	Forward (3'-5')	Reverse (3'-5')
Wnt2b	NM_004185.4	GGGGCACGAGTGATCTGTG	GCATGATGTCTGGGTAACGCT
Lrp5	NM_002335.4	AACGGCAGGACGTGTAAGG	AGCGAGATCCTCCGTAGGTC
Lrp6	NM_002336.3	TTTATGCAAACAGACGGGACTT	GCCTCCAACACTACAATCGTAGC
β-catenin	XM_006712983.2	CATCTACACAGTTTGATGCTGCT	GCAGTTTTGTTCAGTTCAGGGA
Ocn	NM_199173.6	CACTCCTCGCCCTATTGGC	CCCTCCTGCTTGGACACAAAG
Opn	NM_001040058.2	CTCCATTGACTCGAACGACTC	CAGGTCTGCGAAACTTCTTAGAT
Alp	NM_125429.4	ACTGGGGCCTGAGATACCC	TCGTGTTGCACTGGTTAAAGC
Gapdh	NM_002046.7	TGTGTCCGTCGTGGATCTGA	TTGCTGTTGAAGTCGCAGGAG

Supplementary Table 3 The sequencing data of potential target mRNAs of piR-63049 in BMSCs of OVX rats


Gene symbol	Expression trend	Fold change	P-value
Wnt2b	down	-2.90947877	0.00315
Rnf225	down	-2.067328965	0.047589
MacroD2	down	-6.450895959	0.006066
Sema3e	up	2.347193869	0.014987
Dapk2	up	2.428486444	0.040763
LOC108351962	down	-4.430667559	0.009633




Supplementary Figure 1 The backbone of luciferase reporter gene plasmid containing Wnt 3'UTR.




Supplementary Figure 2 The osteogenic differentiation capacity of osteoporotic BMSCs was significantly decreased. **(A)** The bone density of femurs from OVX rats was significantly decreased compared to sham control rats. **(B)** The bone marrow mesenchymal stem cells of OVX and sham control rats. **(C)** Flow cytometry showing that the isolated BMSCs were negative for surface differentiation antigens CD34 and CD45, while they were positive for CD29 and CD90. **(D, E)** Alizarin red staining shows that the BMSCs of OVX rats have decreased osteogenic differentiation capacity compared to those from sham control rats (n=3). **(F)** Expression of the osteogenic marker genes Opn, Runx2, and Alp was significantly reduced in BMSCs of OVX rats (n=3). **(G, H)** The protein levels of osteogenic markers were also significantly decreased in BMSCs of OVX rats (n=3). * p < 0.05, ** p < 0.01, *** p < 0.001.





Supplementary Figure 3 The differential expression profile of mRNAs in BMSCs of OVX rats. **(A)** Volcano plot of mRNAs expressed in BMSCs of OVX rats. **(B)** Heatmap of differentially expressed mRNAs in OVX rats. **(C)** GO enrichment analysis of differentially expressed mRNAs. **(D)** KEGG pathway enrichment analysis of differentially expressed mRNAs.




Supplementary Figure 4 The expression of Wnt1, Wnt2b, Wnt3a, Wnt4, Wnt5a, Wnt6, Wnt7a, Wnt7b, Wnt9a, Wnt11, and Wnt16 after piR-63049 overexpressing or knocking-down (n=6). ** p < 0.01, *** p < 0.001.




Supplementary Figure 5 *In vitro* effects of antagopiR-63049. (A) AntagopiR-63049 transfection significantly suppressed the expression of piR-63049 but promoted the expression of Wnt2b (n=3). (B) The results of ALP staining showed that antagopiR-63049 transfection could significantly promote the osteogenic capability of BMSCs (n=3). *** p < 0.001.



Supplementary Figure 6 Treatment with antagopiR-63049 had no significant impact on primary organs (A) No significant change in tissue weight of internal organs (including heart, liver, spleen, lung, and kidney) was observed in OVX rats treated with antagopiR-63049 (n=6). (B) No significant histological change in key tissues (including heart, liver, spleen, lung, kidney, and muscle) was observed in OVX rats treated with antagopiR-63049 (n=6).



Supplementary Figure 7 Treatment with antagopiR-63049 had no significant impact on the expression of piR-63049 in heart, liver, spleen, lung and kidney (n=6).



Supplementary Figure 8 AntagopiR-63049 treatment inhibits bone resorption. (A) The results of ELISA showed that the expression of CTX-I was significantly increased in OVX rats compared to the Sham group, but could be significantly rescued by antagopiR-63049 treatment (n=6). (B) The results of TRAP staining showed that the number and size of TRAP-positive cells were significantly increased in OVX rats, an effect which could be significantly rescued by antagopiR-63049 treatment (n=6). *** $p < 0.001$.

